

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/435, A61K 38/17	A1	(11) International Publication Number: WO 95/28424 (43) International Publication Date: 26 October 1995 (26.10.95)
(21) International Application Number: PCT/US95/04481 (22) International Filing Date: 12 April 1995 (12.04.95) (30) Priority Data: 08/227,722 14 April 1994 (14.04.94) US (71) Applicant: IMMULOGIC PHARMACEUTICAL CORPORATION [US/US]; 610 Lincoln Street, Waltham, MA 02154 (US). (72) Inventors: CHEN, Xian; 755 Wellman Avenue, North Chelmsford, MA 01863 (US). EVANS, Sean; 6 Lincoln Drive, Acton, MA 01720 (US). SHAKED, Ze'ev; 1038 Sierra Street, Berkely, CA 94707 (US). FRANZEN, Henry, M.; 372 Charles River Road, Watertown, MA 02172 (US). KUO, Mei-chang; 5 Cox Road, Winchester, MA 01890 (US). (74) Agents: VANSTONE, Darlene, A. et al.; Immulogic Pharmaceutical Corporation, 610 Lincoln Street, Waltham, MA 02154 (US).		(81) Designated States: AU, CA, JP, KR, NZ, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: PHARMACEUTICAL PEPTIDE FORMULATIONS FOR TREATMENT OF DUST MITE ALLERGY (57) Abstract The present invention provides novel therapeutic compositions and multi-peptide formulations of peptides and modified peptides of Group I and Group II <i>Der p</i> and <i>Der f</i> derived protein allergens. Such novel therapeutic compositions and multi-peptide formulations are the result of a preformulation scheme to develop an optimized drug product for therapeutic treatment of humans suffering from allergy to house dust mite allergens. The <i>Der p</i> and <i>Der f</i> peptides and modified peptides in accordance with the invention possess certain unique characteristics which render them particularly suitable for drug product formulation. Therapeutic compositions and multi-peptide formulations of the invention have been optimized to accommodate and maintain the unique characteristics of the peptides and modified peptides derived from house dust mite protein allergens and at the same time provide maximum therapeutic effect when used in therapeutic regimens for the treatment of house dust mite allergy in humans. The invention further provides novel modified peptides derived from <i>Der p</i> I and <i>Der p</i> II protein allergens.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

Pharmaceutical Peptide Formulations for Treatment of Dust Mite Allergy

Background of the Invention

5 Approximately 500 million people around the world are allergic to dust mites and it is believed that allergy to dust mites may be a factor in 50% to 80% of patients with asthma as well as a numerous cases of eczema, hay fever, and other allergic symptoms. Dust mites are ubiquitous in homes, and thrive in beds, draperies and
10 carpets. It is extremely difficult to remove them from the living environment and an allergic individual is constantly exposed to the allergen and such constant exposure may cause the allergic condition to worsen with time. Thus, allergy to dust mite may be chronic and difficult to treat.

 Allergy to mites of the genus *Dermatophagoides* has been associated with a number of allergic conditions such as asthma, rhinitis, and ectopic dermatitis. Two
15 species, *D. pteronyssinus* and *D. farinae* predominate and as a result, considerable effort has been expended in trying to identify allergens produced by these two species. Researchers have documented the importance of responses to the Group I (e.g. *Der p* I, and *Der f* I) and Group II (e.g. *Der p* II and *Der f* II) protein allergens. For example, it has been documented that over 60% of patients have at least 50% of their anti-mite
20 antibodies directed toward these proteins (e.g., Lind, P. et al., Allergy, 39:259-274 (1984); van der Zee, J.S. et al., Journal Allergy and Clinical Immunology, 81:884-896 (1988)). It is possible that children show a greater degree of reactivity to the Group I and Group II allergens (Thompson, P.J., et al., Immunology, 64:301-314 (1988)).

 A concerted effort has been made to characterize by gene cloning the
25 major allergens from both *D. pteronyssinus* and *D. farinae*. Consequently, several publications have reported the complete nucleotide sequences of several allergens including *Der p* I (Thomas, W.R., et al., International Archives of Allergy and Applied Immunology, 85:127-129 (1988); and Chua, K.Y., et al., Journal of Experimental Medicine, 167:175-182 (1988)), *Der p* II (Chua, K.Y.,
30 et al., International Archives of Allergy and Applied Immunology, 91:118-123 (1990)), *Der f* I (Dilworth, R.J., et al., Clinical and Experimental Allergy, 21:25-32 (1991)), *Der f* II (Yuuki, T., et al., Japan Journal Allergol., 39:557-461 (1990); and Trudinger, M., et al., Clinical and Experimental Allergy, 21:33-37 (1991)) and a low molecular weight allergen (Ovey, E.R., et al., Journal of
35 Experimental Medicine, 170:1457-1462 (1989)).

 The published nucleotide sequences of cDNAs encoding *Der p* I and *Der f* I demonstrate that these two proteins are highly homologous at the amino acid

level (81% identity) and that the mature protein products are comprised of 222 and 223 residues, respectively (Chua, K.Y., et al., Journal of Experimental Medicine, 167:175-182 (1988); and Dilworth, R.J., et al., supra). The protein allergens *Der p* II and *Der f* II are both comprised of 129 residues, and are also highly homologous (88% identity) in amino acid sequence (Trudinger, M., et al. supra; Yuuki, T., et al. supra); Chua, K.Y., et al, International Archives of Allergy and Applied Immunology, 91:118-123 (1990)).

The isolation of cDNAs clones encoding *Der p* I and *Der p* II has permitted antibody binding studies on the recombinant antigens (Green, W.K., et al., International Archives of Allergy and Applied Immunology, 92:30-38 (1990); Chua, K.Y., et al., International Archives of Allergy and Applied Immunology, 91:124-129 (1990)). Complementary DNA fragments of *Der p* I have been expressed in *E. coli* and IgE binding studies with pooled human mite allergic IgE sera have demonstrated binding and non-binding regions throughout the molecule (Thomas, W.R., et al., In: Epitopes of Atopic Allergens. Proceedings of Workshop from XIV Congress of the European Academy of Allergy and Clinical Immunology, Berlin, Sept. 1989. pp 77-82). T cell epitopes of *Der p* I have been reported (O'Hehir, R.E., et al., Annual Review Immunology, 9:67-95 (1991); Stewart, G.A., et al., In: Epitopes of Atopic Allergens. Proceedings of Workshop from XIV Congress of the European Academy of Allergy and Clinical Immunology, Berlin, Sept. 1989. pp 41-47; Yessel, H., et al., In: T cell Activation in Health and Disease: Discrimination Between Immunity and Tolerance, Conference 22-26 Sept., 1990, Trinity College, Oxford, U.K. and Hessel, H., et al., Journal of Immunology, 148(3): 738-745 (Feb. 1, 1992).

Presently, desensitization therapy is used for the treatment of house dust mite allergy. Such therapy includes administration of an extract derived from whole house dust mite cultures to an allergic individual. Desensitization therapy using such extract has drawbacks in that it can elicit anaphylaxis if high doses are used, whereas when low doses are used to avoid anaphylaxis, treatment is not highly effective and must be continued for several years to build up tolerance to the extract.

WO93/08279 and WO94/24281 disclose improved compositions and methods for treatment of allergy to house dust mite which greatly minimizes the potential adverse effects associated with conventional desensitization therapy using whole house dust mite extract. WO93/08279 and WO94/24281 disclose isolated antigenic fragments or peptide derived from *Der p* I, *Der p* II, *Der f* I and *Der f* II which when

administered to a dust mite sensitive individual, are capable of down regulating the allergic response of the individual to house dust mite. Such down regulation of the allergic response of the individual results in diminution or alleviation of the classic symptoms of allergy including asthmatic symptoms induced by house dust mite. Such antigenic fragments are disclosed in WO93/08279 and WO94/24281 as being capable of eliciting a T cell response such as stimulation (i.e. T cell proliferation or lymphokine secretion) and/or are capable of inducing T cell nonresponsiveness or reduced T cell responsiveness when challenged with a house dust mite allergen. In addition, WO93/08279 and WO94/24281 disclose that the most preferred peptides derived from *Der p* and *Der f* Group I and Group II protein allergens suitable for therapeutic use do not bind IgE specific for such *Der p* and *Der f* proteins, or bind IgE to a substantially lesser extent than the native dust mite protein allergen, thereby reducing or eliminating the possibility of anaphylaxis in a treatment regimen which includes such peptides. Furthermore, WO93/08279 and WO94/24281 disclose that given the cross reactivity within the interspecies Group I allergens (i.e., *Der p* I and *Der f* I) and the interspecies Group II allergens (i.e., *Der p* II and *Der f* II), peptides of Group I, for example, derived from one species (e.g., *Der p* I) are capable of eliciting a T cell response from T cells specific for the other species (e.g., *Der f* I), and vice-versa. Finally, WO93/08279 and WO94/24281 disclose peptides which possess the characteristics described above.

As a result of extensive preformulation efforts, the present invention provides novel compositions and multi-peptide formulations of peptides derived from *Der p* and *Der f* Group I and Group II protein allergens which are optimal for preparation of a drug product suitable for use in treating house dust mite allergy in humans and other mammals. Such novel compositions and multi-peptide formulations of *Der p* and *Der f* protein allergen peptides for use as an optimized human drug product have not previously been disclosed or contemplated.

Summary of the Invention

The present invention provides novel therapeutic compositions and multi-peptide formulations of peptides and modified peptides of Group I and Group II *Der p* and *Der f* derived protein allergens. Such novel therapeutic compositions and multi-peptide formulations are the result of a preformulation scheme to develop an optimized drug product for therapeutic treatment of humans suffering from allergy to house dust mite allergens. The *Der p* and *Der f* peptides and modified peptides in accordance with the invention possess certain unique characteristics which render them particularly suitable for drug product formulation. Therapeutic compositions and

multi-peptide formulations of the invention have been optimized to accommodate and maintain the unique characteristics of the peptides and modified peptides derived from house dust mite protein allergens and at the same time provide maximum therapeutic effect when used in therapeutic regimens for the treatment of house dust mite allergy in humans. The invention further provides novel modified peptides derived from *Der p I* and *Der p II* protein allergens.

Description of the Drawings

Fig. 1 shows the amino acid sequences of the "unique" peptides in accordance with the invention including the novel "unique" peptides of the invention.

Fig. 2 shows overlapping peptides derived *Der p I* and *Der p II* protein allergens used in T cell studies described herein.

Fig. 3 is a graphic representation depicting T cell responses to the overlapping *Der p I* peptides shown in Fig. 2 and the Group I "unique" peptides, DPI-21.2 (SEQ. ID. NO. 27), DFI-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30), shown in Fig. 1. The mean S.I. shown above each bar (in parenthesis) as well as the percentage of responses, the positivity index (mean S.I. multiplied by percentage of responses), is the Y axis.

Fig. 4 is a graphic representation depicting T cell responses to the overlapping *Der p II* peptides, DPII-20.9 (SEQ. ID. NO. 31), DPII-22.14 (SEQ. ID. NO. 32), and DPII-25.15 (SEQ. ID. NO. 33), shown in Fig. 2 and the *Der p II* "unique" peptides shown in Fig. 2. The mean S.I. shown above each bar (in parenthesis) as well as the percentage of responses, the positivity index (mean S.I. multiplied by percentage of responses), is the Y axis.

Fig. 5 is a pH-solubility profile of "unique" candidate peptides DPI-21.2 (SEQ. ID. NO. 27), DFI-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30), DPII-20.9 (SEQ. ID. NO. 31), DPII-22.14 (SEQ. ID. NO. 32) and DPII-25.15 (SEQ. ID. NO. 33), in 50mM sodium phosphate buffers with 5% mannitol. Solubility is measured in mg/ml (y axis) over a pH range of pH 5.5 to pH 8.5 at about 22°C \pm 2.

35

Fig. 6 is a pH-stability profile of candidate peptides DPI-21.2 (SEQ. ID. NO. 27), DFI-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30),

DPII-20.9 (SEQ. ID. NO. 31), DPII-22.14 (SEQ. ID. NO. 32) and DPII-25.15 (SEQ. ID. NO. 33) in an equal concentration combination. Degradation of peptide is calculated as % degradation (determined by peak area using HPLC analysis) of peptide observed after 24 hours at about $22^{\circ}\text{C} \pm 2$ and about 5°C , at various theoretical concentrations of 3.0, 2.0 and 1.0 mg/ml of peptide over a pH range of 6.0 to 8.5.

Detailed Description of the Invention

The patent and scientific literature referred to herein establishes the knowledge that is available to those with skill in the art. The PCT publications and other publications cited herein are hereby incorporated by reference.

The present invention provides novel modified *Der p* I and *Der p* II peptides which are in combination with other *Der p* I and *Der f* I peptides are a part of a preformulation scheme to develop an optimized drug product for therapeutic treatment of humans suffering from allergy to house dust mite allergen. Such peptides and modified peptides possess certain unique characteristics which render them particularly suitable for drug product formulation, and may be referred to herein as "unique" peptides.

In accordance with pharmaceutical chemistry, preformulation is the process of optimizing a drug through determination and/or definition of those physical and chemical properties considered important in the formulation of a stable, effective, and safe dosage form. The possible interactions with the various components intended for use in the final drug product are also considered. Preformulation is an intensive effort that includes the study of such parameters as solubility, pH profile of stability, and drug-excipient interactions, which may have a profound effect on a drug's physiological availability and physical and chemical stability. The data obtained from such studies are integrated with those obtained from preliminary pharmacological and biochemical studies of the active drug component thus providing information that permits the selection of the best drug form, and the most desirable excipients for use in its development.

The development of an optimum formulation of active drug component and excipients is complex and many factors influence formulation properties. The high degree of uniformity, the physiological availability and the therapeutic quality expected of pharmaceuticals can only be achieved by considerable effort and expertise. Flexibility is also an important factor in preformulation. Numerous excipients, stabilizers counter ions and the like may have to be tested in order to find those compatible with the active drug component of the formulation. Multiple modifications of the active component may become necessary to successfully formulate a drug

product. Such modifications must not effect the overall therapeutic effectiveness of the drug but at the same time, must render the drug more suitable for formulation.

As a part of a preformulation scheme to provide an optimized drug product suitable for use in humans and other mammals for treating sensitivity to house dust mite, it was determined that the active component (referred to herein as a "peptide" or "candidate peptide" or "unique peptide") in such formulation should possess the following characteristics which would render such peptides "unique" among all of the possible peptides derived from the *Der p* I, *Der p* II and *Der f* I protein allergen sequences. First, a unique peptide should alone or in combination with other unique peptides comprise a sufficient percentage of the T cell reactivity of the *Der p* and *Der f* protein allergens to induce T cell nonresponsiveness or reduced T cell responsiveness in a substantial percentage of the individuals sensitive to house dust mite allergen. Second, the candidate peptide should possess the characteristic of "superior solubility" which is defined herein as solubility of greater than 3 mg/ml at a pH in a pH range of pH 6 to pH 8 in an aqueous buffer. Third, the peptide is stable in an aqueous buffer at a pH in a pH range from pH 6 to pH 8. Candidate peptides derived from *Der p* and *Der f* protein allergens which have been determined to be "unique" peptides of the invention are DPI-21.2 (SEQ. ID. NO. 27), DFI-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30), DPII-20.9 (SEQ. ID. NO. 31), DPII-22.14 (SEQ. ID. NO. 32) and DPII-25.15 (SEQ. ID. NO. 33) all as shown in Fig. 1.

In accordance with the first characteristic, Those peptides found to elicit a T cell response such as T cell proliferation or lymphokine secretion (i.e. comprise at least one T cell epitope), or induce T cell non-responsiveness or reduced T cell responsiveness are understood to have T cell reactivity. T cell epitopes are believed to be involved in initiation and perpetuation of the immune response to a protein allergen which is responsible for the clinical symptoms of allergy. These T cell epitopes are thought to trigger early events at the level of the T helper cell by binding to an appropriate HLA molecule on the surface of an antigen presenting cell and stimulating the relevant T cell subpopulation. These events lead to T cell proliferation, lymphokine secretion, local inflammatory reactions, recruitment of additional immune cells to the site, and activation of the B cell cascade leading to production of antibodies. One isotype of these antibodies, IgE, is fundamentally important to the development of allergic symptoms and its production is influenced early in the cascade of events, at the level of the T helper cell, by the nature of the lymphokines secreted. A T cell epitope is the basic element or smallest unit of recognition by a T cell receptor, where the epitope comprises amino acids essential to receptor recognition. It is believed that exposure of house dust mite allergic patients to isolated house dust

mite Group I and Group II protein allergen peptides which comprise at least one T cell epitope may cause T cell non-responsiveness of appropriate T cell subpopulations such that they become unresponsive or have reduced responsiveness to the protein allergen and do not participate in stimulating an immune response upon such exposure for
5 example, via anergy, tolerance, or apoptosis, the ability to modify the lymphokine secretion profile as compared with exposure to the naturally occurring autoantigen; and /or the ability to cause induction of T suppresser cells.

To determine peptides having T cell reactivity and comprising at least one T cell epitope, isolated peptides are tested by, for example, T cell biology techniques, to
10 determine whether the peptides elicit a T cell response or induce T cell non-responsiveness. As discussed in the Examples human T cell stimulating activity can be tested by culturing T cells obtained from an individual sensitive to house dust mite allergen, (i.e., an individual who has an IgE mediated immune response to house dust mite allergen) with a peptide or modified peptide derived from a *Der p* or *Der f* Group
15 I or Group II protein allergen and determining whether proliferation of T cells occurs in response to the peptide as measured, e.g., by cellular uptake of tritiated thymidine. Stimulation indices for responses by T cells to peptides can be calculated as the maximum counts per minute (CPM) in response to a peptide divided by the control CPM. A stimulation index (S.I.) equal to or greater than two times the background
20 level is considered "positive". Positive results are used to calculate the mean stimulation index for each peptide for the group of patients tested. Peptides suitable as candidates for formulation into a final drug product have a mean T cell stimulation index of greater than or equal to 2.0 and preferably higher, (e.g. at least 2.5, more preferably at least 3.5, more preferably at least 4.0, more preferably at least 5, even
25 more preferably at least 7 and most preferably at least about 9).

For therapeutic purposes, candidate peptides are recognized by at least 10%, more preferably at least 20%, more preferably at least 30% and even more preferably at least 40% or more of individuals in a population of individuals sensitive to house dust mite allergen. In addition, preferred candidate peptides have a positivity index
30 (P.I.) of at least about 100, more preferably at least about 250 and most preferably at least about 350. The positivity index for a peptide is determined by multiplying the mean T cell stimulation index by the percent of individuals, in a population of individuals sensitive to house dust mite allergen (e.g., preferably at least 15 individuals, more preferably at least 30 individuals or more), who have a T cell
35 stimulation index to such peptide of at least 2.0. Thus, the positivity index represents both the strength of a T cell response to a peptide (S.I.) and the frequency of a T cell

response to a peptide in a population of individuals sensitive to house dust mite allergen.

To determine whether a peptide (candidate peptide) or a combination of candidate peptides are likely to comprise a sufficient percentage of the T cell reactivity of house dust mite protein allergens, to induce T cell nonresponsiveness in a substantial percentage of a population of individuals sensitive to house dust mite allergen, an algorithm can be used. In accordance with one such algorithm, a set of overlapping peptides is produced by systematically dividing the protein allergen(s) of interest into at least two overlapping peptide regions of desired lengths (e.g., of about 12-30 amino acid residues in length, preferably not longer than about 25 amino acid residues in length with about 5-15 amino acid residues of overlap). This division into peptide regions can be arbitrary, can be made according to an algorithm, or can be wholly or partially based on regions of house dust mite Group I and/or Group II protein allergens known to comprise at least one T cell epitope. Preferably, at least 50% of the entire house dust mite protein allergen sequence and more preferably, the entire house dust mite protein allergen sequence is divided into two or more peptides. A human T cell stimulation index is determined for each of the peptides in an *in vitro* T cell proliferation assay as described herein for each individual tested in a population of individuals sensitive to the protein antigen. For example both WO93/08279 and WO94/24281 disclose T cell studies with overlapping peptides derived from *Der p* I, *Der p* II, *Der f* I and *Der f* II. A candidate peptide or combination of candidate peptides is selected based, at least in part, on the mean human T cell stimulation index of the candidate peptide in the set of peptides tested and the positivity index of the candidate peptide in the set of peptides tested (see, Figs. 3 and 4). The human T cell stimulation index for the candidate peptide(s) is summed. For each individual, the human T cell stimulation index for the candidate peptide(s) is divided by the sum of the human T cells stimulation indices of the remaining peptides in the set of peptides tested to determine a percent of T cell reactivity as shown below:

$$(1) \quad \% \text{ T Cell Reactivity of a candidate peptide(s)} = \frac{\text{Candidate S.I.}}{\text{Sum of S.I. of the set of Overlapping peptides}} \times 100$$

Alternatively, the presence of T cell epitopes in the candidate peptide dependent on amino acids residues in an overlapping peptide located at either the N-terminus or C-terminus of the candidate peptide in the amino acid sequence of the protein antigen, but which epitopes are not present in the candidate peptide can be

considered in calculating the percent of T cell reactivity in the candidate peptide by use of the following formula:

$$\begin{aligned} (2) \quad \% \text{ T Cell Reactivity of a candidate peptide(s)} = & \\ 5 \quad & \frac{N_T \text{ flanking peptide S.I.} + \text{Candidate peptide S.I.} + C_T \text{ flanking peptide S.I.}}{\text{Sum of S.I. of the set of overlapping peptides}} \times 100 \end{aligned}$$

10 In this formula, "N_T flanking peptide" refers to a peptide which comprises amino acid residues which overlap with amino acid residues located at the N-terminus of the candidate peptide in the amino acid sequence of the protein antigen from which the peptide is derived; "C_T flanking peptide" refers to a peptide which comprises amino acid residues which overlap with amino acid residues located at the C-terminus of the candidate peptide in the amino acid sequence of the protein antigen from which the peptide is derived. In this calculation stimulation indices for the candidate peptide, the N-terminal flanking peptide and the C-terminal flanking peptide are added and divided by the sum total of the stimulation indices for the entire set of overlapping peptides obtain a percent of T cell reactivity for the candidate peptide. If a combination of two or more candidate peptides is selected each of which contains amino acid residues which overlap, this calculation cannot be used to determine a percent of T cell reactivity for each candidate peptide separately. However, a total percent of T cell reactivity for the combination of candidate peptides can be obtained. In this situation, the stimulation indices for all of the candidate peptides which overlap is included in the calculation.

25 The values obtained for the percentage of T cell reactivity for the candidate peptide or combination of peptides in each individual tested can be expressed as a range of the lower and higher values of the results of the above described calculations. By either of the above calculations, the percent is obtained for at least about twenty (20) and preferably at least about thirty (30) individuals sensitive to the protein antigen and a mean percent is determined. For use in the compositions of the invention, the candidate peptide or combination of candidate peptides has the following criteria: (1) the candidate peptide or combination of candidate peptides has a mean percent of at least about 10%, preferably at least about 20%, more preferably at least about 30%, more preferably at least about 40% and more preferably at least about 50-60% or greater; and (2) in the population of individuals tested at least about 60%, preferably at least about 75%, and more preferably at least about 90-100% have positive T cell responses (S.I. equal to or greater than 2.0) in response to the candidate peptide or combination of candidate peptides. A candidate peptide or combination of candidate

peptides meeting the above criteria is likely to comprise a sufficient percentage of the T cell reactivity to house dust mite protein allergen to induce T cell non-responsiveness or reduced T cell responsiveness in a substantial percentage of a population of individuals sensitive to house dust mite.

- 5 As an illustrative embodiment of the above-described algorithm, a set of overlapping peptides and candidate peptides derived from *Der p* I and *Der p* II respectfully were produced and tested. Secondary T cell cultures determined to be reactive with *Der p* I protein allergen were derived from 39 house dust mite-allergic subjects and analyzed for reactivity to an overlapping set of peptides, as well as
- 10 candidate peptides derived from *Der p* I and *Der f* I protein allergen, DPI-21.2 (SEQ. ID. NO. 27), DFI-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29) and DPI-26.6 (SEQ. ID. NO. 30), in an in vitro T cell proliferation assay as described herein. The results are shown in Fig. 3. The highest stimulation index greater than or equal to 2.0 in response to each peptide was recorded for each subject tested. The data were then
- 15 analyzed by the equations above. The results and calculations of the percent of T cell reactivity for a single dust mite-allergic subject are shown below using formulas (1) and (2).

T CELL REACTIVITY FOR PATIENT 1733

20

PEPTIDE STIMULATION INDEX

DPI-21.2 (SEQ. ID. NO. 27)	3.6
DPI-3 (SEQ. ID. NO. 3)	3.9
DPI-22.2 (SEQ. ID. NO. 28)	3.1
DPI-12.1 (SEQ. ID. NO. 6)	2.2
DPI-5.1 (SEQ. ID. NO. 7)	3.5
DPI-23.31 (SEQ. ID. NO. 29)	5.7
DPI-14 (SEQ. ID. NO. 9)	2.3
DPI-15 (SEQ. ID. NO. 10)	2.8
DPI-6.1 (SEQ. ID. NO. 11)	2.1
DPI-7.1 (SEQ. ID. NO. 12)	2.2
DPI-26.6 (SEQ. ID. NO. 30)	5.0
DPI-9 (SEQ. ID. NO. 14)	2.4
DPI-16 (SEQ. ID. NO. 15)	2.0
DPI-10 (SEQ. ID. NO. 16)	0
DPI-17 (SEQ. ID. NO. 17)	0
SUM OF STIMULATION INDICES	40.8 (DENOMINATOR)

% Reactivity of Peptide DPI-26.6 (SEQ. ID. NO. 30) for patient 1733 is

$$(1) \quad \frac{\text{DPI-26.6 (S.I.)}}{40.8} = \frac{5.0}{40.8} \times 100 = 12.3\%$$

$$(2) \quad \frac{\text{DPI-7.1+DPI-26.6+DPI-9}}{40.8} = \frac{2.2+5.0+2.4}{40.8} \times 100 = 24\%$$

15

Therefore the estimated range of T cell reactivity for Peptide DPI-26.6 (SEQ. ID. NO. 30) for this patient is 12.3%-24% of the total reactivity of the *Der p* I protein. The above calculation is repeated for any potential candidate peptides for each patient tested. In the population of 39 Cry j I-allergic subjects tested the following results were obtained:

20

	<u>Candidate Peptides</u>	<u>Range of mean percentage T Cell Reactivity</u>	<u>Frequency of response at least one peptide</u>
25	DPI-21.2 (SEQ. ID. NO. 27), DFI-22.2 (SEQ. ID. NO. 28) DPI-23.31 (SEQ. ID. NO. 29),		
30	DPI-26.6 (SEQ. ID. NO. 30)	38-67%	82%

Thus, the combination of the four candidate peptides are well within the desired range for possessing, in combination, sufficient T cell reactivity of Group I protein allergen of *Der f* and *Der p*, and meet the first characteristic of a "unique" peptide of the invention.

The same calculation were determined for the Group II, *Der p* protein allergen. Secondary T cell cultures determined to be reactive with *Der p* I protein allergen were derived from 30 house dust mite-allergic subjects and analyzed for reactivity to an overlapping set of peptides, as well as candidate peptides derived from *Der p* II, DPII-20.9 (SEQ. ID. NO. 31), DPII-22.14 (SEQ. ID. NO. 32) and DPII-25.15 (SEQ. ID. NO. 33), in an in vitro T cell proliferation assay as described herein. The results are shown in Fig.4. The highest stimulation index greater than or equal to 2.0 in response to each peptide was recorded for each subject tested. The data were then analyzed by the

following results were obtained:

	Candidate <u>Peptides</u>	Range of mean percentage <u>T Cell Reactivity</u>	Frequency of response <u>at least one peptide</u>
5	DPII-20.9 (SEQ. ID. NO. 31), DPII-22.14 (SEQ. ID. NO. 32)		
10	DPII-25.15 (SEQ. ID. NO. 33)	37-51%	63%

Thus, the combination of the three *Der p* II candidate peptides of the invention are well within the desired range for possessing, in combination, sufficient T cell reactivity of Group II house dust mite protein allergen of *Der p*, and meet the first characteristic of a "unique" peptide of the invention.

For the treatment of allergy in accordance with the methods of the invention, it is preferred that a peptide used in conjunction therewith does not bind immunoglobulin E (IgE) or binds IgE to a substantially lesser extent (i.e. at least 100-fold less binding and more preferably, at least 1,000-fold less binding) than the respective house dust mite protein allergen from which the peptide is derived binds IgE. The major complications of standard immunotherapy are IgE-mediated responses such as anaphylaxis. Immunoglobulin E is a mediator of anaphylactic reactions which result from the binding and cross-linking of antigen to IgE on mast cells or basophils and the release of mediators (e.g., histamine, serotonin, eosinophil chemotactic factors) in allergic ("atopic") patients. Thus, anaphylaxis in a substantial percentage of a population of individuals sensitive to the allergen being treated could be avoided by the use in immunotherapy of a peptide or peptides which do not bind IgE in a substantial percentage (e.g., at least about 75%) of a population of individuals sensitive to house dust mite allergen, or if the peptide binds IgE, such binding does not result in the release of mediators from mast cells or basophils. The risk of anaphylaxis could be reduced by the use in immunotherapy of a peptide or peptides which have reduced IgE binding. IgE binding may be tested, for example by direct ELISA or capture ELISA. Moreover, peptides which have minimal IgE stimulating activity are desirable for therapeutic effectiveness. Minimal IgE stimulating activity refers to IgE production that is less than the amount of IgE production and/or IL-4 production stimulated by the native respective house dust mite protein allergen. If a peptide binds IgE, it is preferable that such binding does not result in the release of mediators (e.g. histamines) from mast cells or basophils. To determine whether a peptide that binds IgE causes

the release of mediators, a histamine release assay can be performed using standard reagents and protocols obtained for example, from Amac, Inc. (Westbrook, ME). Briefly, a buffered solution of a peptide to be tested is combined with an equal volume of whole heparinized blood from an allergic subject. After mixing and incubation, the cells are pelleted and the supernatants are processed and analyzed using a radio immunoassay to determine the amount of histamine released. Experiments to date indicate that candidate peptides DPI-21.2 (SEQ. ID. NO. 27), DFI-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30), DPII-20.9 (SEQ. ID. NO. 31), DPII-22.14 (SEQ. ID. NO. 32) and DPII-25.15 (SEQ. ID. NO. 33) exhibit negative IgE reactivity or histamine release (data not shown).

The second characteristic for a unique peptide is that of "superior solubility" which was defined earlier as being solubility of greater than 3 mg/ml at a pH in a range of pH 6 to pH 8. Solubility in a physiologically acceptable pH range (e.g. pH 6 to pH 8) is particularly important when formulating a multi-peptide therapeutic for injection. Administration of a soluble drug product in a physiologically acceptable pH range by intravenous or subcutaneous injection provides about 100% bioavailability of the drug component to the physiological system into which the drug is being introduced. Thus, it is necessary that a drug product intended for injection be fluid to the extent that easy syringability exists, and the active component be soluble as well if maximum therapeutic effect is to be achieved. Solubility is also useful when formulating compositions to be administered via other modes of administration such as by oral administration (tablet, aerosol, sublingual), or sustained release preparations and formulations.

Proteins and peptides may be difficult to formulate into soluble compositions as a peptide may not be soluble in any desirable pH range or may be soluble in only a narrow pH range. It is particularly difficult when multiple peptides are being formulated together into a single multi-peptide formulation, as each peptide may be soluble in a pH range which does not overlap with those of the other peptides in the formulation. As a result, it is the requirement of "superior solubility" which requires the most formulation flexibility in that considerable modification of the targeted candidate peptides may be necessary to successfully formulate a multi-peptide drug product.

Some of the unique peptides of the invention are the product of multiple amino acid modifications of the original targeted candidate peptide sequence ("parent") from which the modified unique peptides of the invention were originally derived. Such modified "unique" peptides of the invention include DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30), DPII-20.9 (SEQ. ID. NO. 31), DPII-22.14 (SEQ. ID.

NO. 32) and DP11-25.15 (SEQ. ID. NO. 33) all as shown in Fig. 1. For example, the amino acid sequence of Dp11-22.14 (SEQ. ID. NO. 32) was derived from the protein sequence of *Der p* II by first identifying those regions of the native protein with high T-cell reactivity using a set of overlapping peptides that covered the entire protein sequence. Several peptides were found to exhibit high T-cell reactivity, corresponding to three different locations/areas in the protein. One of these areas were covered by three adjacent peptides each being about 25-29 amino acids long and with 10-15 amino acids overlap, Dp11-3.1 (SEQ. ID. NO. 20), Dp11-4 (SEQ. ID. NO. 21) and Dp11-5 (SEQ. ID. NO. 22) (Fig. 2) that all exhibited high T-cell reactivity. Based on this T-cell map a new peptide was synthesized, with the amino acid sequence QLEAVFEANQNTKTAKIEIKASIDGLEV (SEQ. ID. NO. 34), 28 amino acids long, which exhibits most of the reactivity found in the individual peptides (data not shown) and contains all of Dp11-4 (SEQ. ID. NO. 21) and parts of Dp11-3.1 (SEQ. ID. NO. 20) and Dp11-5 (SEQ. ID. NO. 22). However, this peptide did not meet the "superior solubility" requirement of 3 mg/ml for a "unique peptide of the invention nor did it meet the stability requirement. Therefore two analogs were made with addition of one or two charged residues at each end, Dp11-22.2 KQLEAVFEANQNTKTAKIEIKASIDGLEVK (SEQ. ID. NO. 35) and Dp11-22.6 DKQLEAVFEANQNTKTAKIEIKASIDGLEVD (SEQ. ID. NO. 36) and the stability improved substantially but the solubility did not reach the standard of a "superior solubility". In the second attempt a series of truncated analogs with up to five charged amino acid residues added to the ends (Table 1).

DpII-22 (SEQ. ID. NO. 34)	QLEAVFEANQNTKTAKIEIKASIDGLEV
DpII-22.2 (SEQ. ID. NO. 35)	KQLEAVFEANQNTKTAKIEIKASIDGLEVK
DpII-22.6 (SEQ. ID. NO. 36)	DKQLEAVFEANQNTKTAKIEIKASIDGLEVD
DpII-22.4 (SEQ. ID. NO. 37)	QLEAVFEANQNTKTAKIEIKASIDE
DpII-22.5 (SEQ. ID. NO. 38)	DKQLEAVFEANQNTKTAKIEIKASIDE
DpII-22.8 (SEQ. ID. NO. 39)	DKEQLEAVFEANQNTKTAKIEIKASIDE
DpII-22.9 (SEQ. ID. NO. 40)	DKEQLEAVFEANQNTKTAKIEIKASIDEE
DpII-22.12 (SEQ. ID. NO. 41)	DKQLEAVFEANQATKTAKIEIKASIDE
DpII-22.16 (SEQ. ID. NO. 42)	DKELEAVFEANQNTKTAKIEIKASD
DpII-22.19 (SEQ. ID. NO. 43)	DKELEAVFEANQNTKTAKIEIKAD
DpII-22.20 (SEQ. ID. NO. 44)	DKELEAVFEANQNTKTAKIEIKAK
DpII-22.21 (SEQ. ID. NO. 45)	DKELEAVFEANQNTKTAKIEIKD
DpII-22.22 (SEQ. ID. NO. 46)	DKELEAVFEANQNTKTAKIEIKK
DpII-22.26 (SEQ. ID. NO. 47)	DKELEAVFEANQNTKTAKIEIK
DpII-22.23 (SEQ. ID. NO. 48)	DKELEAVFEANQNTKTAKIED
DpII-22.24 (SEQ. ID. NO. 49)	DKELEAVFEANQNTKTAKIEK
DpII-22.25 (SEQ. ID. NO. 50)	DKELEAVFEANQNTKTAKIE
DpII-22.14 (SEQ. ID. NO. 32)	DKELEAVFEANQNTKTAKAE
DpII-22.10 (SEQ. ID. NO. 51)	LEAVFEANQNTKTAK
DpII-22.11 (SEQ. ID. NO. 52)	LEAVFEANQATKTAK
DpII-22.18 (SEQ. ID. NO. 53)	DKTAKIEIKASIDGLE
DpII-22.15 (SEQ. ID. NO. 54)	KTAKIEIKASIDGLE

Table 1

Of these the DpII-22.5, DKQLEAVFEANQNTKTAKIEIKASIDE (SEQ. ID. NO. 38),
5 was promising since it retained the T-cell reactivity of the "parent" peptide, DpII-22,
(SEQ. ID. NO. 34) and was very soluble, but it was very difficult to synthesize. The
difficulties in synthesizing this sequence were found to disappear with the replacement
of the hydrophobic isoleucine with the less hydrophobic alanine and simultaneously
the solubility increased by an order of magnitude. Peptide DpII-22.14,
10 DKELEAVFEANQNTKTAKAE (SEQ. ID. NO. 32), was found to possess almost the

same T-cell reactivity as the "parent" peptide DpII-22 (SEQ. ID. NO. 34) as well as being soluble at greater than 3 mg/ml at a pH in the pH range 6.0 to 8.0, and was easy to synthesize and purify. Therefore, DpII-22 (SEQ. ID. NO. 34) was chosen as a "unique" peptide when it was determined to be stable at a pH in the range of 6.0 to 8.0.

5 The development of the other modified "unique" peptides, DpI-23.31 (SEQ. ID. NO. 29), DpI-26.6 (SEQ. ID. NO. 30) and DpII-25.15 (SEQ. ID. NO. 33), followed a process similar to that described above for DpII-22.14 (SEQ. ID. NO. 32). Peptides DpII-22.14 (SEQ. ID. NO. 32), DpI-23.31 (SEQ. ID. NO. 29), DpI-26.6 (SEQ. ID. NO. 30) and DpII-25.15 (SEQ. ID. NO. 33), all as shown in Fig. 1 are novel modified
10 peptides of this invention.

The third criteria which the unique peptides of this invention must meet is stability, particularly solution stability, in a physiologically acceptable pH range of pH 6 to pH 8. It must be stable under the conditions of manufacture and storage, and under conditions of reconstitution if necessary. Stability testing establishes the time
15 period for which the integrity, quality and purity of the drug product is preserved in its finished dosage form. Stability testing may be performed concurrently with solubility studies as discussed in Example 3. An equal concentration composition comprising each of the candidate peptides of the invention remained stable (e.g. no significant degradation) in solution at a common "window" within the pH range from pH 6-pH 8
20 at about room temperature and at about 5°C for at least 24 hours (see, Fig. 6).

Therefore, candidate peptides DPI-21.2 (SEQ. ID. NO. 27), DFI-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30), DpII-20.9 (SEQ. ID. NO. 31), DpII-22.14 (SEQ. ID. NO. 32) and DpII-25.15 (SEQ. ID. NO. 33) possess each of the three required "unique" characteristics outlined above, indicating
25 that this combination of peptides is suitable for formulation as an optimized therapeutic drug product for administration to humans for treatment of allergy to house dust mite allergen.

Highly purified peptides of this invention, may be produced synthetically by chemical synthesis using standard techniques. Various methods of chemically
30 synthesizing peptides are known in the art such as solid phase synthesis which has been fully or semi automated on commercially available peptide synthesizers. Synthetically produced peptides may then be purified to homogeneity (i.e. at least 90%, more preferably at least 95% and even more preferably at least 97% purity), free from all other polypeptides and contaminants using any number of techniques known
35 in the literature for protein purification.

In accordance with one procedure for producing highly purified homogenous peptides of the invention, a peptide produced by synthetic chemical means (either

anchored to a polymer support "solid phase synthesis" or by conventional homogenous chemical reactions "solution synthesis") may be purified by preparative reverse phase chromatography. In this method, the synthetically produced peptide in "crude" form is dissolved in an appropriate solvent (typically an aqueous buffer) and applied to a separation column (typically a reverse phase silica based media, in addition, polymer or carbon based media may be used). Peptide is eluted from the column by increasing the concentration of an organic component (typically acetonitrile or methanol) in an aqueous buffer (typically TFA, triethylamine phosphate, acetate or similar buffer). Fractions of the eluate will be collected and analyzed by appropriate analytical methods (typically reverse phase HPLC or CZE chromatography). Those fractions having the required homogeneity will be pooled. The counter ion present may be changed by additional reverse phase chromatography in the salt of choice or by ion exchange resins. The peptide may then be isolated as its acetate or other appropriate salt. The peptide is then filtered and the water removed (typically by lyophilization) to give a homogenous peptide composition containing at least 90%, more preferably at least 95% and even more preferably at least 97% of the required peptide component. Optionally, or in conjunction with reverse phase HPLC as described above, purification may be accomplished by affinity chromatography, ion exchange, size exclusion, counter current or normal phase separation systems, or any combination of these methods. Peptide may additionally be concentrated using ultra filtration, rotary evaporation, precipitation, dialysis or other similar techniques.

The highly purified homogenous peptide composition is then characterized by any of the following techniques or combinations thereof: a) mass spectroscopy to determine molecular weight to check peptide identity; b) amino acid analysis to check the identity of the peptide via amino acid composition; c) amino acid sequencing (using an automated protein sequencer or manually) to confirm the defined sequence of amino acid residues; d) HPLC (multiple systems if desired) used to check peptide identity and purity (i.e. identifies peptide impurities); e) water content to determine the water concentration of the peptide compositions; f) ion content to determine the presence of salts in the peptide composition; and g) residual organics to check for the presence of residual organic reagents, starting materials, and/or organic contaminants.

A peptide of the invention may also be produced by recombinant DNA techniques in a host cell transformed with a nucleic acid sequence coding for such peptide. When produced by recombinant techniques, host cells transformed with nucleic acid encoding the desired peptide are cultured in a medium suitable for the cells and isolated peptides can be purified from cell culture medium, host cells, or both using techniques known in the art for purifying peptides and proteins including ion-

exchange chromatography, ultra filtration, electrophoresis or immunopurification with antibodies specific for the desired peptide. Peptides produced recombinantly may be isolated and purified to homogeneity, free of cellular material, other polypeptides or culture medium for use in accordance with the methods described above for synthetically produced peptides.

In certain limited circumstances, peptides of this invention may also be produced by chemical or enzymatic cleavage of a highly purified full length or native protein of which the sites of chemical digest or enzymatic cleavage have been predetermined and the resulting digest is reproducible. Peptides having defined amino acid sequences can be highly purified and isolated free of any other poly peptides or contaminants present in the enzymatic or chemical digest by any of the procedures described above for highly purified, and isolated synthetically or recombinantly produced peptides.

The present invention also pertains to therapeutic compositions and multi-peptide therapeutic formulations comprising the unique peptides of the invention. Therapeutic compositions of the invention may comprise one or more of the unique peptides of the invention which may be administered simultaneously or sequentially as single treatment episode for treatment of allergy to house dust mite allergen in a human or other mammal. Such a treatment regimen may not necessarily be a physical mixture of more than one peptide of the invention, but does comprise a combination of such peptides administered simultaneously or sequentially as a single treatment episode in order to achieve the maximum therapeutic effect the combination of the unique peptides, DPI-21.2 (SEQ. ID. NO. 27), DFI-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30), DPII-20.9 (SEQ. ID. NO. 31), DPII-22.14 (SEQ. ID. NO. 32) and DPII-25.15 (SEQ. ID. NO. 33) provide (e.g. solubility and stability in acceptable physiological pH range as well as having a range of T cell reactivity of 38-67% of the total T cell reactivity of the Group I house dust mite protein allergen and a frequency of response of 91% for at least one *Der p* I peptide tested in a population of individuals allergic to house dust mite and similarly, have a range of T cell reactivity of 37-51% of the total T cell reactivity of the Group II house dust mite protein allergen and a frequency of response of 63% for at least one *Der p* II peptide tested in a population of individuals allergic to house dust mite).

Therapeutic compositions of the invention comprise one or more of peptides DPI-21.2 (SEQ. ID. NO. 27), DFI-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30), DPII-20.9 (SEQ. ID. NO. 31), DPII-22.14 (SEQ. ID. NO. 32) and DPII-25.15 (SEQ. ID. NO. 33) also comprise one or more pharmaceutically acceptable carriers such as excipients which are compatible with

peptide or peptides present in a single composition. When the composition is a multi-peptide formulation, the pharmaceutically acceptable carrier must be compatible with all of the peptides in the multi-peptide formulation. Preferred excipients include but are not limited to sterile water, sodium phosphate, mannitol, or both sodium phosphate and mannitol or any combination thereof. Other suitable excipients include but are not limited to sorbitol, sucrose, dextrose, lactose dextran and PVP. Additionally, due to the potential for dimerization of the peptides in a multi-peptide formulation, there may also be included an agent such as EDTA to prevent dimerization. Alternatively, any other material or procedures known in the art to prevent dimerization may be used. In addition, pharmaceutically acceptable counter ions may be added during the preparation of the multi-peptide formulation. Examples of pharmaceutically acceptable counter ions include acetate, HCl, and citrate.

A therapeutic composition of the invention should be sterile, stable under conditions of manufacture, storage, distribution and use and should be preserved against the contaminating action of microorganisms such as bacteria and fungi. A preferred means for manufacturing a therapeutic compositions of the invention in order to maintain the integrity of the composition (i.e. prevent contamination, prolong storage, etc.) is to prepare the formulation of peptide and pharmaceutically acceptable carrier(s) such that the composition may be in the form of a lyophilized powder which is reconstituted in a pharmaceutically acceptable carrier, such as sterile water, just prior to use. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying, freeze-drying or spin drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

A preferred multi-peptide formulation comprises the following unique peptides DPI-21.2 (SEQ. ID. NO. 27), DFI-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30), DPII-22.14 (SEQ. ID. NO. 32) and DPII-25.15 (SEQ. ID. NO. 33) and sodium phosphate and mannitol, and optionally may further comprise DPII-20.9 (SEQ. ID. NO. 31). For this embodiment, EDTA is added to the formulation. A suitable counter ion such as acetate may also be added during the preparation of the formulation. The formulation is preferably prepared in the form of a lyophilized powder which is reconstituted in a physiologically acceptable carrier, such as sterile water, prior to use. Several non-limiting examples of a preferred multi-peptide formulations of this invention are described below. The unique house dust mite protein allergen peptides will preferably be combined during manufacturing with the appropriate counter ion to produce one vial containing a sterile, pyrogen free, and preferably lyophilized powder of the desired formulation:

5 **Active:** *Der p I*, *Der f I* and *Der p II* peptides DPI-21.2 (SEQ. ID. NO. 27), DFI-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30), DPII-22.14 (SEQ. ID. NO. 32) and DPII-25.15 (SEQ. ID. NO. 33)

In concentration of 0.75 mg per peptide

10 **Inactives:** 0.05 M Sodium Phosphate U.S.P.
5% w/v Mannitol, U.S.P.
0.1 mg/ml EDTA disodium dihydrate U.S.P.
Final pH 7.2 -7.4

Diluent: Sterile Water for Injection, U.S.P.

15 **Optionally** 0.75 mg of DPII-20.9 (SEQ. ID. NO. 31) may be added to the active ingredients.

A preferred combination of multi-peptide formulations suitable for administration simultaneously or sequentially as a single treatment episode and contained in two separate sterile, pyrogen free vials preferably in the form of lyophilized powders include the following formulations:

20 **Vial #1**

Active: *Der p I*, *Der f I* and *Der p II* peptides DFI-22.2(SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), and DPII-22.14 (SEQ. ID. NO. 32)

In concentration of 0.75 mg per peptide

25 **Inactives:** 0.05 M Sodium Phosphate U.S.P.
5% w/v Mannitol, U.S.P.
0.1 mg/ml EDTA disodium dihydrate
Final pH 7.0

Diluent: Sterile Water for Injection, U.S.P.

Vial #2

- Active:** *Der p I*, and *Der p II* peptides DPI-21.2 (SEQ. ID. NO. 27), DPI-26.6 (SEQ. ID. NO. 30), DPII 20.9 (SEQ. ID. NO. 31), DPII-25.15 (SEQ. ID. NO. 33)
- 5 In concentration of 0.75 mg per peptide
- Inactives:** 0.05 M Sodium Phosphate U.S.P.
 5% w/v Mannitol, U.S.P.
 0.1 mg/ml EDTA disodium dihydrate U.S.P.
 Final pH 6.2
- 10 **Diluent:** Sterile Water for Injection, U.S.P.

The multipeptide formulations of the invention may also be provided in the form of a kit, including instructions for use.

- Administration of the therapeutic compositions and multipeptide formulations described above to an individual, preferably in non-immunogenic form, can be carried out using known procedures at dosages and for periods of time effective to cause down regulation of the house dust mite-specific immune response (i.e., reduce the allergic symptoms caused by house dust mite protein allergen of the individual. Down regulation of the allergic immune response to house dust mite allergen in humans may be determined clinically whenever possible (see e.g., Varney et al, *British Medical Journal*, 302:265-269 (1990), or may be determined subjectively (i.e. the patient feels as if some or all of the allergic symptoms caused by house dust mite allergens have been alleviated).

- One of the unique characteristics of each unique peptide in accordance with the invention is that each peptide possesses "superior solubility". Therefore, compositions and multipeptide formulations of the invention are particularly suitable for administration by injection (e.g. subcutaneous, or intravenous). However, optimized compositions and multipeptide formulations of the invention may be administered in any convenient manner wherein solubility of the active drug component is either desirable or acceptable, such as by injection (subcutaneous, intravenous, etc.), oral administration, sublingual, inhalation, transdermal application, rectal administration, or any other route of administration known in the art for administering soluble therapeutic agents. It may be desirable to administer simultaneously or sequentially a therapeutically effective amount of one or more of the therapeutic compositions of the invention to an individual as a single treatment episode. Each of such compositions for administration simultaneously or sequentially as a single treatment episode, may

comprise only one unique peptide of the invention or may comprise an optimized multi-peptide formulation in accordance with the invention.

For subcutaneous injection of one or more therapeutic compositions and multi-peptide formulations of the invention, preferably about 1 μ g- 3 mg and more preferably from about 20 μ g-1.5 mg, and even more preferably about 50 μ g- 750 μ g of each active component (peptide) per dosage unit may be administered. It is especially advantageous to formulate parenteral compositions in unit dosage form for ease of administration and uniformity of dosage. Unit dosage form as used herein refers to physically discrete units suited as unitary dosages for human subjects to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the desired pharmaceutical carrier. The specification for the novel unit dosage forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of human subjects.

To administer a composition of the invention by other than parenteral administration, (i.e. by oral administration) it may be necessary to coat the composition with, or co-administer the composition with, a material to prevent its inactivation or enhance its absorption and bioavailability. For example, a peptide formulation may be co-administered with enzyme inhibitors or in liposomes. Enzyme inhibitors include pancreatic trypsin inhibitor, diisopropylfluorophosphate (DEP) and trasylol. Liposomes include water-in-oil-in-water CGF emulsions as well as conventional liposomes (Strejan et al., (1984) J. Neuroimmunol., 7:27). When a peptide is suitably protected, the peptide may be orally administered, for example, with an inert diluent or an assimilable edible carrier. The peptide and other ingredients may also be enclosed in a hard or soft shell gelatin capsule, compressed into tablets, or incorporated directly into the individual's diet. For oral therapeutic administration, the active compound may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, solutions, gels, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 1% by weight of active compound. The percentage of the composition and preparations may, of course, be varied and may conveniently be between about 5 to 80% of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that a suitable dosage will be obtained. In addition, the active compound may be incorporated into sustained-release or controlled release (steady state or pulsatile release) preparations and formulations.

Effective amounts of the optimized drug compositions of the invention will vary according to factors such as the degree of sensitivity of the individual to the antigen, the age, sex, and weight of the individual, and the ability of peptide to cause down regulation of the antigen specific immune response in the individual. Dosage regimen may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered over the course of days, weeks, months or years, or the dose may be proportionally increased or reduced with each subsequent injection as indicated by the exigencies of the therapeutic situation. In one preferred therapeutic regimen, subcutaneous injections of therapeutic compositions are given once a week for 3-6 weeks. The dosage may remain constant for each injection or may increase or decrease with each subsequent injection. A booster injection may be administered at intervals of about three months to about one year after initial treatment and may involve only a single injection or may involve another series of injections similar to that of the initial treatment.

This invention is illustrated by the following non-limiting examples.

Example 1

Determination of the percentage of total house dust mite Group I T cell reactivity and patient coverage of the combination of unique *Der p* I and *Der f* I peptides.

Synthesis of Overlapping Peptides

Der p I was divided into a set of 17 overlapping peptides. Overlapping peptides and *Der p* I and *Der f* I unique peptides (i.e. DPI-21.2 (SEQ. ID. NO. 27), DFI-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30)) were synthesized using standard Fmoc/tBoc synthetic chemistry and purified by Reverse Phase HPLC. Figure 1 shows the unique *Der p* I, and *Der f* I peptides and Figure 2 shows the overlapping *Der p* I peptides used in these studies. The peptide names are consistent throughout.

T cell responses to Group I overlapping peptides and unique peptides

Peripheral blood mononuclear cells (PBMC) were purified by Ficoll-Hypaque centrifugation of 60 ml of heparinized peripheral blood from house dust mite-allergic individuals who exhibited clinical symptoms of mite allergy and who were skin test positive for house dust mite.

10^7 PBMC from each patient were cultured in 5 ml RPMI-1640 containing 5% pooled human AB serum and supplemented with glutamine, penicillin, streptomycin and HEPES buffer in the presence of 20 µg/ml purified

native *Der p* I/ml at 37°C for 6 days. Viable cells were then purified by Ficoll-Hypaque centrifugation and cultured for 2-3 additional weeks in RPMI-1640/5% AB serum containing 5 units recombinant human IL-2/ml and 5 units recombinant human IL-4/ml. The resting T cells were then tested in a
5 secondary proliferation assay to assess T cell responses to purified native *Der p* I, overlapping peptides and unique peptides. For assay, 2×10^4 resting T cells were cultured in 200 μ l of RPMI-1640/5% AB serum for 3 days at 37°C in the presence of 2×10^4 autologous Epstein-Barr virus transformed B cells (20,000 Rads) or in the presence of 5×10^4 PBMC (3500 Rads) as antigen presenting
10 cells with various concentrations of purified native *Der p* I or synthetic *Der p* I: unique peptide or overlapping peptides. Each well then received 1 μ Ci tritiated thymidine for 16 hours. The counts incorporated were collected onto glass fiber filters and processed for liquid scintillation counting. Medium alone, acting as negative control, contained no allergen or peptide. The results are
15 shown in Fig. 3. The highest stimulation index greater than or equal to 2.0 in response to each peptide was recorded for each subject tested. The data were then analyzed by the equations described earlier in the specification.

The combination of Group I candidate peptides DPI-21.2 (SEQ. ID. NO. 27), DFI-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29) DPI-26.6
20 (SEQ. ID. NO. 30), had a range of T cell reactivity of about 38-67% based on an analysis of 39 patients, the frequency of response at 82% represents reactivity to at least one of the candidate peptides, indicating that this combination of peptides fits the first criteria for "unique" peptides of the invention in that the combination of peptides DPI-21.2 (SEQ. ID. NO. 27),
25 DFI-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30), comprise a sufficient percentage of the total T cell reactivity to Group I protein allergens from *Der p* and *Der f* in a substantial percentage of the population tested.

30

Example 2

Determination of the percentage of total house dust mite Group II T cell reactivity and patient coverage of the combination of unique *Der p* I candidate peptides

35 Synthesis of Overlapping Peptides

Der p II was divided into a set of 9 overlapping peptides. Overlapping *Der p* II peptides and *Der p* II unique peptides (i.e. DPII-20.9 (SEQ. ID. NO. 31), DPII-22.14

(SEQ. ID. NO. 32), and DP11-25.15 (SEQ. ID. NO. 33)) were synthesized using standard Fmoc/tBoc synthetic chemistry and purified by Reverse Phase HPLC. Figure 1 shows the unique *Der p* II peptides and Figure 2 shows the overlapping *Der p* II peptides used in these studies. The peptide names are consistent throughout.

5

T cell responses to Group II overlapping peptides and unique candidate peptides

Secondary *Der p* II reactive T cell cultures derived from 30 mite-allergic patients were analyzed for reactivity to an overlapping set of *Der p* II peptides and *Der p* II candidate peptides. in an in vitro T cell proliferation assay as described in Example 1. The results are shown in Fig. 4. The highest stimulation index greater than or equal to 2.0 in response to each peptide was recorded for each subject tested. The data were then analyzed by the equations described earlier in the specification.

The combination of candidate peptides DP11-20.9 (SEQ. ID. NO. 31), DP11-22.14 (SEQ. ID. NO. 32), and DP11-25.15 (SEQ. ID. NO. 33), had a range of T cell reactivity of about 36%-51% based on an analysis of 30 patients (Fig. 4). The frequency of response to at least one of the candidate peptides was about 63%, indicating that this combination of peptides fits the first criteria for "unique" peptides of the invention, in that the combination of *Der p* II peptides DP11-20.9 (SEQ. ID. NO. 31), DP11-22.14 (SEQ. ID. NO. 32), and DP11-25.15 (SEQ. ID. NO. 33), comprise a sufficient percentage of the total T cell reactivity to *Der p* II in a substantial percentage of the population tested.

Example 3

Determination of pH-solubility and pH-stability profiles of candidate peptides of the invention

1. Buffer Preparation

50 mM sodium phosphate stock solutions:

Stock solution A: 0.66 g (0.05 mol) of monobasic sodium phosphate monohydrate U.S.P. and 50 mg EDTA disodium dihydrate, U.S.P. were dissolved in 100 mL of WFI. The solution was filtered through a 0.2 micron filter

Stock solution B: 0.71 g (0.05 mol) of dibasic sodium phosphate U.S.P. were dissolved in 100ml WFI. The solution was filtered through a 0.2 micron filter.

2. Initial peptide dispersions

Dispersion A: 3.0 mg of each candidate peptide, DPI-21.2 (SEQ. ID. NO. 27), DFI-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO.

30), DPII-20.9 (SEQ. ID. NO. 31), DPII-22.14 (SEQ. ID. NO. 32) and DPII-25.15 (SEQ. ID. NO. 33), was weighed out separately and placed in separate 1.5 mL eppendoff vials with 600 μ L of stock solution A. The composition was agitated for 5 seconds to mix well.

5 Dispersion B: 3.0 mg of each peptide, DPI-21.2 (SEQ. ID. NO. 27), DFI-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30), DPII-20.9 (SEQ. ID. NO. 31), DPII-22.14 (SEQ. ID. NO. 32) and DPII-25.15 (SEQ. ID. NO. 33), was weighed out separately and placed in separate 1.5 mL eppendoff vials with 600 μ L of stock solution B. The mixture was agitated for 5 seconds to mix well.

10 Dispersions A and B were sonicated for 2 minutes for good homogeneity. A small volume was pipetted from each dispersion into a labeled eppendoff vial according to the following volume ratio:

Vial #	Suspension A (μ L)	Suspension B (μ L)	Total Volume (μ L)	Estimated final pH
1	100	0	100	5.2
2	80	20	100	6.2
3	60	40	100	6.6
4	40	60	100	6.8
5	20	80	100	7.1
6	0	100	100	8.0

15 The resultant solutions/suspensions were stored in the dark at about $22^{\circ}\text{C} \pm 2$ for 24 hours without agitation. The solutions were filtered and filtrates were analyzed for pH and peptide concentration.

The concentration of filtered peptide solutions was determined by HPLC analysis. In this experiment, the solubility of peptide at each pH is defined as the amount of peptide remaining in solution after filtration through a membrane filter having a 0.2 micrometer pore size. The extent of degradation of peptides was estimated by calculating the percent of total degradant peak area over the total peak area.

25 The pH values with respect to the solubility values was plotted and are shown in Fig. 5 for each respective peptide. As shown in the solubility curve for each peptide as represented in Fig. 5, peptides DPI-21.2 (SEQ. ID. NO. 27), DFI-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30), DPII-20.9 (SEQ. ID. NO. 31), DPII-22.14 (SEQ. ID. NO. 32) and DPII-25.15 (SEQ. ID. NO. 33) are each soluble at greater than 3 mg/ml at a pH in the pH range of pH 6 to pH 8.

30 The pH-stability profiles for each peptide DPI-21.2 (SEQ. ID. NO. 27), DFI-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30),

DPII-20.9 (SEQ. ID. NO. 31), DPII-22.14 (SEQ. ID. NO. 32) and DPII-25.15 (SEQ. ID. NO. 33) in equal concentration combination at 3, 2, and 1 mg/ml per peptide and prepared in duplicate as described above with one set stored at about 5° C for 24 hours and one set stored at about 22°C ± 2 for 24 hours, were calculated and tabulated as a function of the percentage of total of degradant peak area (Fig. 6). As can be seen from the data in Fig. 6, the percent degradation of peptide at each concentration was less for peptides stored at about 5°C for 24 hours as compared to peptides stored at 22° C ± 2 for 24 hours over the critical pH range of pH 6.0 to pH 8.0. However, acceptable solution stability is demonstrated for all the peptides in a common "window" within the pH range of pH 6 to pH 8 at either temperature.

Therefore, each of peptides DPI-21.2 (SEQ. ID. NO. 27), DFI-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30), DPII-20.9 (SEQ. ID. NO. 31), DPII-22.14 (SEQ. ID. NO. 32) and DPII-25.15 (SEQ. ID. NO. 33) was determined to possess the appropriate solubility and stability required of a unique peptide of the invention.

Although the invention has been described with reference to its preferred embodiments, other embodiments, can achieve the same results. Variations and modifications to the present invention will be obvious to those skilled in the art and it is intended to cover in the appended claims all such modification and equivalents and follow in the true spirit and scope of this invention.

SEQUENCE LISTING

5 (1) GENERAL INFORMATION:

(1) GENERAL INFORMATION:

(i) APPLICANT:

10 (A) NAME: IMMULOGIC PHARMACEUTICAL CORPORATION
(B) STREET: 610 Lincoln Street
(C) CITY: Waltham
(D) STATE: MA
(E) COUNTRY: USA
15 (F) POSTAL CODE (ZIP): 02154
(G) TELEPHONE: (617) 466-6000
(H) TELEFAX: (617) 466-6040

20 (ii) TITLE OF INVENTION: PHARMACEUTICAL PEPTIDE FORMULATIONS FOR
TREATMENT OF DUST MITE ALLERGY

(iii) NUMBER OF SEQUENCES: 54

25 (iv) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
30 (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(vi) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 08/227,772
(B) FILING DATE: April 14, 1994

35 (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Vanstone, Darlene A.
(B) REGISTRATION NUMBER: 35,279
(C) REFERENCE/DOCKET NUMBER: 017.5 PCT

40 (ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: (617) 466-6000
(B) TELEFAX: (617) 466-6010

45 (2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:
50 (A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

55 (v) FRAGMENT TYPE: internal

60 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

Thr Asn Ala Cys Ser Ile Asn Gly Asn Ala Pro Ala Glu Ile Asp
1 5 10 15

Leu Arg Gln Met Arg
20

5 (2) INFORMATION FOR SEQ ID NO: 2:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 27 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

10

- (ii) MOLECULE TYPE: peptide

15

- (v) FRAGMENT TYPE: internal

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Glu Ile Asp Leu Arg Gln Met Arg Thr Val Thr Pro Ile Arg Met Gln
 1 5 10 15

25

Gly Gly Cys Gly Ser Cys Trp Ala Phe Ser Gly
 20 25

(2) INFORMATION FOR SEQ ID NO: 3:

30

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 29 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

35

- (ii) MOLECULE TYPE: peptide

- (v) FRAGMENT TYPE: internal

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

45

Thr Val Thr Pro Ile Arg Met Gln Gly Gly Cys Gly Ser Cys Trp Ala
 1 5 10 15

50

Phe Ser Gly Val Ala Ala Thr Glu Ser Ala Tyr Leu Ala
 20 25

(2) INFORMATION FOR SEQ ID NO: 4:

55

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 21 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

60

- (ii) MOLECULE TYPE: peptide

- (v) FRAGMENT TYPE: internal

65

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Val Ala Ala Thr Glu Ser Ala Tyr Leu Ala His Arg Asn Gln Ser Leu

1 5 10 15

Asp Leu Ala Glu Gln
20

5

(2) INFORMATION FOR SEQ ID NO: 5:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

10

- (ii) MOLECULE TYPE: peptide

15

- (v) FRAGMENT TYPE: internal

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

His Arg Asn Gln Ser Val Asp Leu Ala Glu Gln Glu Leu Val Asp Cys
1 5 10 15

25

Ala Ser Gln His Gly Cys
20

30

(2) INFORMATION FOR SEQ ID NO: 6:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 21 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

35

- (ii) MOLECULE TYPE: peptide

- (v) FRAGMENT TYPE: internal

40

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

45

Glu Leu Val Asp Cys Ala Ser Gln His Gly Cys His Gly Asp Thr Ile
1 5 10 15

50

Pro Arg Gly Ile Glu
20

(2) INFORMATION FOR SEQ ID NO: 7:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

55

- (ii) MOLECULE TYPE: peptide

60

- (v) FRAGMENT TYPE: internal

65

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

Glu Tyr Ile Gln His Asn Gly Val Val Gln Glu Ser Tyr Tyr Arg Tyr
 1 5 10 15

Val Ala Arg Glu
 20

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

His Asn Gly Val Val Gln Glu Ser Tyr Tyr Arg Tyr Val Ala Arg Glu
 1 5 10 15

Gln Ser Cys Arg Arg Pro Asn Ala Gln
 20 25

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

Gln Ser Cys Arg Arg Pro Asn Ala Gln Arg Phe Gly Ile Ser Asn Tyr
 1 5 10 15

Cys Gln Ile

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

Arg Phe Gly Ile Ser Asn Tyr Gys Gln Ile Tyr Pro Pro Asn Ala Asn
 1 5 10 15

5 Lys Ile Arg Glu Ala Leu
 20

(2) INFORMATION FOR SEQ ID NO: 11:

10 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 24 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

25 Tyr Pro Pro Asn Ala Asn Lys Ile Arg Glu Ala Leu Ala Gln Thr His
 1 5 10 15

Ser Ala Ile Ala Val Ile Ile Gly
 20

30

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 26 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

Ala Gln Thr His Ser Ala Ile Ala Val Ile Ile Gly Ile Lys Asp Leu
 1 5 10 15

50

Asp Ala Phe Arg His Tyr Asp Gly Arg Thr
 20 25

(2) INFORMATION FOR SEQ ID NO: 13:

55

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 26 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

60

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

65

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

Ile Lys Asp Leu Asp Ala Phe Arg His Tyr Asp Gly Arg Thr Ile Ile
 1 5 10 15
 Gln Arg Asp Asn Gly Tyr Gln Pro Asn Tyr
 20 25

10 (2) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 23 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: peptide

20 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

Ile Ile Gln Arg Asp Asn Gly Tyr Gln Pro Asn Tyr His Ala Val Asn
 1 5 10 15
 Ile Val Gly Tyr Ser Asn Ala
 20

(2) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 22 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

His Ala Val Asn Ile Val Gly Tyr Ser Asn Ala Gln Gly Val Asp Tyr
 1 5 10 15
 Trp Ile Val Arg Asn Ser
 20

55 (2) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 24 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

65 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

5 Gln Gly Val Asp Tyr Trp Ile Val Arg Asn Ser Trp Asp Thr Asn Trp
 1 5 10 15
 Gly Asp Asn Gly Tyr Gly Tyr Phe
 20

10 (2) INFORMATION FOR SEQ ID NO: 17:

 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 26 amino acids
 (B) TYPE: amino acid
 15 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

 (ii) MOLECULE TYPE: peptide

20 (v) FRAGMENT TYPE: internal

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

 Gly Asp Asn Gly Tyr Gly Tyr Phe Ala Ala Asn Ile Asp Leu Met Met
 1 5 10 15
 30 Ile Glu Glu Tyr Pro Tyr Val Val Ile Leu
 20 25

(2) INFORMATION FOR SEQ ID NO: 18:

35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 20 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 40 (D) TOPOLOGY: linear

 (ii) MOLECULE TYPE: peptide

 (v) FRAGMENT TYPE: internal

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

50 Asp Gln Val Asp Val Lys Asp Cys Ala Asn His Glu Ile Lys Lys Val
 1 5 10 15
 Leu Val Pro Gly
 20

55

(2) INFORMATION FOR SEQ ID NO: 19:

 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 25 amino acids
 60 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

 (ii) MOLECULE TYPE: peptide

65

 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

5 His Glu Ile Lys Lys Val Leu Val Pro Gly Cys His Gly Ser Glu Pro
1 5 10 15
Cys Ile Ile His Arg Gly Lys Pro Phe
20 25

10

(2) INFORMATION FOR SEQ ID NO: 20:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 amino acids
15 (B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

His Gly Ser Glu Pro Cys Ile Ile His Arg Gly Lys Pro Phe Gln Leu
1 5 10 15
30 Glu Ala Val Phe Glu Ala Asn Gln Asn Thr Lys Thr Ala
20 25

35 (2) INFORMATION FOR SEQ ID NO: 21:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 amino acids
40 (B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

50

Gln Leu Glu Ala Val Phe Glu Ala Asn Gln Asn Thr Lys Thr Ala Lys
1 5 10 15

55

Ile Glu Ile Lys Ala Ser Ile Asp Gly
20 25

(2) INFORMATION FOR SEQ ID NO: 22:

(i) SEQUENCE CHARACTERISTICS:
60 (A) LENGTH: 27 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

65

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

5 Lys Ile Glu Ile Lys Ala Ser Ile Asp Gly Leu Glu Val Asp Val Pro
 1 5 10 15
 Gly Ile Asp Pro Asn Ala Cys His Tyr Met Lys
 20 25

10 (2) INFORMATION FOR SEQ ID NO: 23:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 26 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

15 (ii) MOLECULE TYPE: peptide

20 (v) FRAGMENT TYPE: internal

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

 Leu Glu Val Asp Val Pro Gly Ile Asp Pro Asn Ala Cys His Tyr Met
 1 5 10 15
 Lys Cys Pro Leu Val Lys Gly Gln Gln Tyr
 20 25

(2) INFORMATION FOR SEQ ID NO: 24:

35 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 27 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

40 (ii) MOLECULE TYPE: peptide

 (v) FRAGMENT TYPE: internal

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

50 Cys Pro Leu Val Lys Gly Gln Gln Tyr Asp Ile Lys Tyr Thr Trp Asn
 1 5 10 15
 Val Pro Lys Ile Ala Pro Lys Ser Glu Asn Val
 20 25

55

(2) INFORMATION FOR SEQ ID NO: 25:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 26 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

60

(ii) MOLECULE TYPE: peptide

65

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

5 Asp Ile Lys Tyr Thr Trp Asn Val Pro Lys Ile Ala Pro Lys Ser Glu
1 5 10 15
Asn Val Val Val Thr Val Lys Val Met Gly
20 25

10

(2) INFORMATION FOR SEQ ID NO: 26:

(i) SEQUENCE CHARACTERISTICS:
15 (A) LENGTH: 25 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: peptide
(v) FRAGMENT TYPE: internal

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

30 Val Val Thr Val Lys Val Met Gly Asp Asp Gly Val Leu Ala Cys Ala
1 5 10 15
Ile Ala Thr His Ala Lys Ile Arg Asp
20 25

35 (2) INFORMATION FOR SEQ ID NO: 27:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
40 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide
45 (v) FRAGMENT TYPE: internal

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

Ser Ile Asn Gly Asn Ala Pro Ala Glu Ile Asp Leu Arg Gln Met Arg
1 5 10 15
Thr Val Thr Pro Ile Arg Met Gln
55 20

(2) INFORMATION FOR SEQ ID NO: 28:

60 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 amino acids/
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

65 (ii) MOLECULE TYPE: peptide
(v) FRAGMENT TYPE: internal

15 (A) LENGTH: 26 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: peptide
 (v) FRAGMENT TYPE: internal

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

30 Asp Glu Glu Gly Val Val Gln Glu Ser Tyr Tyr Arg Tyr Val Ala Arg
 1 5 10 15
 Glu Gln Ser Cys Arg Arg Pro Asn Ala Glu
 20 25

35 (2) INFORMATION FOR SEQ ID NO: 30:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 26 amino acids
 (B) TYPE: amino acid
 40 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

45 (v) FRAGMENT TYPE: internal

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

Asp Glu Gly Ile Lys Asp Leu Asp Ala Phe Arg His Tyr Asp Gly Arg
 1 5 10 15
 Thr Ile Ile Gln Arg Asp Asn Gly Tyr Glu
 20 25

(2) INFORMATION FOR SEQ ID NO: 31:

60 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 25 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

65 (ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31:

5 Asp Gln Val Asp Val Lys Asp Cys Ala Asn His Glu Ile Lys Lys Val
 1 5 10 15
 Leu Val Pro Gly Cys His Gly Ser Glu
 20 25

10

(2) INFORMATION FOR SEQ ID NO: 32:

(i) SEQUENCE CHARACTERISTICS:

15 (A) LENGTH: 20 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32:

25

Asp Lys Glu Leu Glu Ala Val Phe Glu Ala Asn Gln Asn Thr Lys Thr
 1 5 10 15

Ala Lys Ala Glu
 20

30

(2) INFORMATION FOR SEQ ID NO: 33:

(i) SEQUENCE CHARACTERISTICS:

35 (A) LENGTH: 28 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

40

(v) FRAGMENT TYPE: internal

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33:

50 Asp Glu Glu Thr Val Lys Val Met Gly Asp Asp Gly Val Leu Ala Cys
 1 5 10 15

Ala Ile Ala Thr His Ala Lys Ile Arg Asp Glu Glu
 20 25

55 (2) INFORMATION FOR SEQ ID NO: 34:

(i) SEQUENCE CHARACTERISTICS:

60 (A) LENGTH: 28 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

65

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34:

5 Gln Leu Glu Ala Val Phe Glu Ala Asn Gln Asn Thr Lys Thr Ala Lys
1 5 10 15
Ile Glu Ile Lys Ala Ser Ile Asp Gly Leu Glu Val
20 25

10 (2) INFORMATION FOR SEQ ID NO: 35:

(i) SEQUENCE CHARACTERISTICS:
15 (A) LENGTH: 30 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide
20 (v) FRAGMENT TYPE: internal

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35:

Lys Gln Leu Glu Ala Val Phe Glu Ala Asn Gln Asn Thr Lys Thr Ala
1 5 10 15
30 Lys Ile Glu Ile Lys Ala Ser Ile Asp Gly Leu Glu Val Lys
20 25 30

(2) INFORMATION FOR SEQ ID NO: 36:

35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 31 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
40 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide
(v) FRAGMENT TYPE: internal

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36:

50 Asp Lys Gln Leu Glu Ala Val Phe Glu Ala Asn Gln Asn Thr Lys Thr
1 5 10 15
Ala Lys Ile Glu Ile Lys Ala Ser Ile Asp Gly Leu Glu Val Asp
20 25 30

55

(2) INFORMATION FOR SEQ ID NO: 37:

(i) SEQUENCE CHARACTERISTICS:
60 (A) LENGTH: 25 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide
65 (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37:

5 Gln Leu Glu Ala Val Phe Glu Ala Asn Gln Asn Thr Lys Thr Ala Lys
 1 5 10 15
 Ile Glu Ile Lys Ala Ser Ile Asp Glu
 20 25

10

(2) INFORMATION FOR SEQ ID NO: 38:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 27 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

15

(ii) MOLECULE TYPE: peptide

20

(v) FRAGMENT TYPE: internal

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38:

30 Asp Lys Gln Leu Glu Ala Val Phe Glu Ala Asn Gln Asn Thr Lys Thr
 1 5 10 15
 Ala Lys Ile Glu Ile Lys Ala Ser Ile Asp Glu
 20 25

35

(2) INFORMATION FOR SEQ ID NO: 39:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 28 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

40

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39:

50

50 Asp Lys Glu Gln Leu Glu Ala Val Phe Glu Ala Asn Gln Asn Thr Lys
 1 5 10 15
 Thr Ala Lys Ile Glu Ile Lys Ala Ser Ile Asp Glu
 20 25

55

(2) INFORMATION FOR SEQ ID NO: 40:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 29 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

60

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

65

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40:

Asp Lys Glu Gln Leu Glu Ala Val Phe Glu Ala Asn Gln Asn Thr Lys
1 5 10 15
Thr Ala Lys Ile Glu Ile Lys Ala Ser Ile Asp Glu Glu
20 25

(2) INFORMATION FOR SEQ ID NO: 41:

15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

20 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41:

30 Asp Lys Gln Leu Glu Ala Val Phe Glu Ala Asn Gln Ala Thr Lys Thr
1 5 10 15
Ala Lys Ile Glu Ile Lys Ala Ser Ile Asp Glu
20 25

35 (2) INFORMATION FOR SEQ ID NO: 42:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 amino acids
(B) TYPE: amino acid
40 (C) STRANDEDNESS:
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

45 (v) FRAGMENT TYPE: internal

50 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42:

Asp Glu Lys Leu Glu Ala Val Phe Glu Ala Asn Gln Asn Thr Lys Thr
1 5 10 15
Ala Lys Ile Glu Ile Lys Ala Ser Asp
20 25

(2) INFORMATION FOR SEQ ID NO: 43:

60 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
65 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43:

Asp Lys Glu Leu Glu Ala Val Phe Glu Ala Asn Gln Asn Thr Lys Thr
1 5 10 15

10 Ala Lys Ile Glu Ile Lys Ala Asp
20

(2) INFORMATION FOR SEQ ID NO: 44:

15 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
20 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44:

30 Asp Lys Glu Leu Glu Ala Val Phe Glu Ala Asn Gln Asn Thr Lys Thr
1 5 10 15

Ala Lys Ile Glu Ile Lys Ala Lys
20

35

(2) INFORMATION FOR SEQ ID NO: 45:

(i) SEQUENCE CHARACTERISTICS:
40 (A) LENGTH: 23 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

45

(v) FRAGMENT TYPE: internal

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45:

Asp Lys Glu Leu Glu Ala Val Phe Glu Ala Asn Gln Asn Thr Lys Thr
1 5 10 15

55

Ala Lys Ile Glu Ile Lys Asp
20

(2) INFORMATION FOR SEQ ID NO: 46:

60

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS:
65 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46:

Asp Lys Glu Leu Glu Ala Val Phe Glu Ala Asn Gln Asn Thr Lys Thr
1 5 10 15

10

Ala Lys Ile Glu Ile Lys Lys
20

15

(2) INFORMATION FOR SEQ ID NO: 47:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

20

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47:

30

Asp Lys Glu Leu Glu Ala Val Phe Glu Ala Asn Gln Asn Thr Lys Thr
1 5 10 15

35

Ala Lys Ile Glu Ile Lys
20

(2) INFORMATION FOR SEQ ID NO: 48:

(i) SEQUENCE CHARACTERISTICS:

40

(A) LENGTH: 21 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS:

(D) TOPOLOGY: linear

45

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48:

55

Asp Lys Glu Leu Glu Ala Val Phe Glu Ala Asn Gln Asn Thr Lys Thr
1 5 10 15

Ala Lys Ile Glu Asp
20

60

(2) INFORMATION FOR SEQ ID NO: 49:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 21 amino acids

(B) TYPE: amino acid

65

(C) STRANDEDNESS:

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49:

10 Asp Lys Glu Leu Glu Ala Val Phe Glu Ala Asn Gln Asn Thr Lys Thr
 1 5 10 15
 Ala Lys Ile Glu Lys
 20

15 (2) INFORMATION FOR SEQ ID NO: 50:

20 —(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 20 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

25 (v) FRAGMENT TYPE: internal

30 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50:

35 Asp Lys Glu Leu Glu Ala Val Phe Glu Ala Asn Gln Asn Thr Lys Thr
 1 5 10 15
 Ala Lys Ile Glu
 20

(2) INFORMATION FOR SEQ ID NO: 51:

40 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

45 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

50

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51:

55 Leu Glu Ala Val Phe Glu Ala Asn Gln Asn Thr Lys Thr Ala Lys
 1 5 10 15

(2) INFORMATION FOR SEQ ID NO: 52:

60 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 15 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS:
 (D) TOPOLOGY: linear

65 (ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52:

Leu Glu Ala Val Phe Glu Ala Asn Gln Ala Thr Lys Thr Ala Lys
1 5 10 15

10 (2) INFORMATION FOR SEQ ID NO: 53:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 16 amino acids
(B) TYPE: amino acid
15 (C) STRANDEDNESS:
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

20 (v) FRAGMENT TYPE: internal

25 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53:

Asp Lys Thr Ala Lys Ile Glu Ile Lys Ala Ser Ile Asp Gly Leu Glu
1 5 10 15

30 (2) INFORMATION FOR SEQ ID NO: 54:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
35 (B) TYPE: amino acid
(C) STRANDEDNESS:
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

40 (v) FRAGMENT TYPE: internal

45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54:

Lys Thr Ala Lys Ile Glu Ile Lys Ala Ser Ile Asp Gly Leu Glu
1 5 10 15

50

What is claimed is:

1. A therapeutic composition comprising at least one isolated peptide selected from the group consisting of: DPI-21.2 (SEQ. ID. NO. 27) and DFI-22.2 (SEQ. ID. NO. 28), and at least one peptide selected from the group consisting of: DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30), DPII-20.9 (SEQ. ID. NO. 31), DPII-22.14 (SEQ. ID. NO. 32) and DPII-25.15 (SEQ. ID. NO. 33) all as shown in Fig. 1.
2. A therapeutic composition comprising peptides DPI-21.2 (SEQ. ID. NO. 27), DFI-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30), DPII-22.14 (SEQ. ID. NO. 32) and DPII-25.15 (SEQ. ID. NO. 33).
3. The therapeutic composition of claim 2 further comprising DPII-20.9 (SEQ. ID. NO. 31).
4. A method of treating sensitivity to house dust mite allergen in a mammal comprising administering simultaneously or sequentially at least two different compositions of claim 1.
5. A method of treating sensitivity to house dust mite allergen in a mammal comprising administering a therapeutic composition of claim 2.
6. A method of treating sensitivity to house dust mite allergen in a mammal comprising administering a therapeutic composition of claim 3.
7. A multipeptide formulation for pharmaceutical administration comprising at least one isolated peptide selected from the group consisting of: DPI-21.2 (SEQ. ID. NO. 27) and DFI-22.2 (SEQ. ID. NO. 28), and at least one peptide selected from the group consisting of: DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30), DPII-20.9 (SEQ. ID. NO. 31), DPII-22.14 (SEQ. ID. NO. 32) and DPII-25.15 (SEQ. ID. NO. 33), each peptide being soluble and stable at a physiologically acceptable predetermined pH, and wherein said formulation comprises a sufficient percentage of T cell activity of Group I and Group II *Der f* and *Der p* house dust mite allergens; and a pharmaceutically acceptable carrier.
8. The multipeptide formulation of claim 7 further comprising EDTA.

9. The multipeptide formulation of claim 7 further comprising a pharmaceutically acceptable counter ion.
10. The multipeptide formulation of claim 7 wherein said predetermined pH is a
5 pH in the range of pH 6.0 to pH 8.0.
11. The multipeptide of claim 7 wherein said sufficient percentage of T cell activity is at least 37%.
- 10 12. The multipeptide formulation of claim 7 comprising peptides DPI-21.2 (SEQ. ID. NO. 27), DFI-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30), DPII-22.14 (SEQ. ID. NO. 32) and DPII-25.15 (SEQ. ID. NO. 33) all as shown in Fig. 1.
- 15 13. The multipeptide formulation of claim 7 further comprising peptide DPII-20.9 (SEQ. ID. NO. 31).
14. An optimized multipeptide formulation suitable for therapeutic treatment of humans suffering from allergy to house dust mite comprising:
20 Peptides DPI-21.2 (SEQ. ID. NO. 27), DFI-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30), DPII-22.14 (SEQ. ID. NO. 32) and DPII-25.15 (SEQ. ID. NO. 33), each peptide in a concentration of 0.75 mg per peptide;
 0.05 M sodium phosphate U.S.P.;
 5 w/v Mannitol, U.S.P.;
25 0.1 mg/ml EDTA disodium dihydrate U.S.P.; and
 Sterile Water for injection U.S.P;
 wherein said formulation has a final pH of 7.2-7.4.
15. An optimized multipeptide formulation of claim 14 further comprising peptide
30 DPII-20.9 (SEQ. ID. NO. 31).
16. An optimized multipeptide formulation suitable for therapeutic treatment of humans suffering from allergy to house dust mite comprising:
 Peptides DFI-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), and
35 DPII-22.14 (SEQ. ID. NO. 32), each peptide in a concentration of 0.75 mg per peptide;
 0.05 M sodium phosphate U.S.P.;

5% w/v Mannitol, U.S.P.;
0.1 mg/ml EDTA disodium dihydrate U.S.P.; and
Sterile Water for injection U.S.P.;

wherein said formulation has a final pH of 7.0.

5

17. An optimized multipeptide formulation suitable for therapeutic treatment of humans suffering from allergy to house dust mite comprising:

Peptides DPI-21.2 (SEQ. ID. NO. 27), DPI-26.6 (SEQ. ID. NO. 30), and DPII-25.15 (SEQ. ID. NO. 33), each peptide in a concentration of 0.75 mg per peptide;

10 0.05 M sodium phosphate U.S.P.;
5% w/v Mannitol, U.S.P.;
0.1 mg/ml EDTA disodium dihydrate U.S.P.; and
Sterile Water for injection U.S.P.;

wherein said formulation has a final pH of 6.2

15

18. A method of treating sensitivity to house dust mite allergy in an individual comprising administering an optimized multipeptide formulation of claim 14.

19. A method of treating sensitivity to house dust mite allergy in an individual comprising administering simultaneously or sequentially, as a single treatment episode, first and second optimized multipeptide formulations wherein said first formulation comprises:

20 peptides DFI-22.2 (SEQ. ID. NO. 28), DPI-23.31 (SEQ. ID. NO. 29), and
DPII-22.14 (SEQ. ID. NO. 32), each peptide in a concentration of 0.75 mg per peptide;
25 0.05 M sodium phosphate U.S.P.;
5% w/v Mannitol, U.S.P.;
0.1 mg/ml EDTA disodium dihydrate U.S.P.; and
Sterile Water for injection U.S.P.; having a final pH of 7.0;

and wherein said second optimized multipeptide formulation comprises:

30 Peptides DPI-21.2 (SEQ. ID. NO. 27), DPI-26.6 (SEQ. ID. NO. 30), and DPII-
25.15 (SEQ. ID. NO. 33), each peptide in a concentration of 0.75 mg per peptide;
0.05 M sodium phosphate U.S.P.;
5% w/v Mannitol, U.S.P.;
0.1 mg/ml EDTA disodium dihydrate U.S.P.; and
35 Sterile Water for injection U.S.P.; having a final pH of 6.2.

20. Use of a multipeptide formulation of claim 7 for the manufacture of a medicament for treatment of sensitivity of an individual to house dust mite allergen.
21. Use of an optimized multipeptide formulation of claim 14, for the manufacture of a medicament for treatment of sensitivity of an individual to house dust mite allergen.
22. An isolated peptide having an amino acid sequence selected from the group consisting of: DPI-23.31 (SEQ. ID. NO. 29), DPI-26.6 (SEQ. ID. NO. 30), DPII-20.9 (SEQ. ID. NO. 31), DPII-22.14 (SEQ. ID. NO. 32) and DPII-25.15 (SEQ. ID. NO. 33).

Fig. 1

NAME	SEQUENCE
DPI-21.2	SINGNAPAEIDLRQMRTVTPIRMQ
DFI-22.2	VAATESAYLAYRNTSLDLSEQELVD
DPI-23.31	DEEGVVQESYYRYVAREQSCRRPNAE
DPI-26.6	DEGIKDLDAFRHYDGRTIIQRDNGYE
DPII-20.9	DQVDVKDCANHEIKKVLVPGCHGSE
DPII-22.14	DKELEAVFEANQNTKTAKAE
DPII-25.15	DEETVKVMGDDGVLACAIATHAKIRDEE

Fig. 2

Peptide Name	
DPI-1 (1-20)	TNAC SINGNAPAEIDLRQMR
DPI-2 (13-39)	EIDLRQMRTVTPIRMQGGCGSCWAFSG
DPI-3 (21-49)	TVTPIRMQGGCGSCWAFSGVAATESAYLA
DPI-4 (40-60)	VAATESAYLAHRNQSLDLAEQ
DPI-11.1 (50-71)	HRNQSVDLAEQELVDCASQHG C
DPI-12.1 (61-81)	ELVDCASQHGCHGDTIPRGIE
DPI-5.1 (81-100)	EYIQHNGVVQESYYRYVARE
DPI-13 (85-109)	HNGVVQESYYRYVAREQSCRRPNAQ
DPI-14 (101-119)	QSCRRPNAQRFGISNYCQI
DPI-15 (110-131)	RFGISNYCQIYPPNANKIREAL
DPI-6.1 (120-143)	YPPNANKIREALAQTHSAIAVIIG
DPI-7.1 (132-157)	AQTHSAIAVIIGIKDLDAFRHYDGRT
DPI-8 (144-169)	IKDLDAFRHYDGRTIIQRDNGYQPNY
DPI-9 (158-180)	IIQRDNGYQPNYHAVNIVGYSNA
DPI-16 (170-191)	HAVNIVGYSNAQGVVDYWIVRNS
DPI-10 (181-204)	QGVVDYWIVRNSWDTNWGDNGYGYF
DPI-17 (197-222)	GDNGYGYFAANIDLMMIEEYPYVVIL
DPII-1 (1-20)	DQVDVKDCANHEIKKVLVPG
DPII-2 (11-35)	HEIKKVLVPGCHGSEPCIIHRGKPF
DPII-3.1 (22-50)	HGSEPCIIHRGKPFQLEAVFEANQNTKTA
DPII-4 (36-60)	QLEAVFEANQNTKTAKIEIKASIDG
DPII-5 (51-77)	KIEIKASIDGLEVDVPGIDPNACHYMK
DPII-6 (61-86)	LEVDVPGIDPNACHYMKCPLVKGQQY
DPII-7 (78-104)	CPLVKGQQYDIKYTWNVVPKIAPKSENV
DPII-8 (87-112)	DIKYTWNVVPKIAPKSENVVVTVKVMG
DPII-9 (105-129)	VVTVKVMGDDGVLACAIATHAKIRD

Fig. 3




Fig. 4




Fig. 5





Fig. 6



INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 95/04481

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07K14/435 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE WPI Section Ch, Week 9415 Derwent Publications Ltd., London, GB; Class B04, AN 94-126807 & ZA,A,9 302 677 (IMMULOGIC PHARM CORP) , 26 January 1994 see abstract	1,4,7,19
X	WO,A,93 08279 (IMMUNOLOGIC PHARMACEUTICAL CORPORATION) 29 April 1993 cited in the application see claims 1,4,84,85 --- -/--	1,4,7,19

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

20 July 1995

Date of mailing of the international search report

01.08.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Moreau, J

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	MOLECULAR IMMUNOLOGY, vol. 29, no. 6, June 1992 OXFORD (GB), pages 739-749, JEANNIN P. ET AL. 'Specific histamine release capacity of peptides selected from the modified Der P I protein ...' see the whole document ---	1-22
A	WO,A,92 04445 (WESTERN AUSTRALIAN RESEARCH INSTITUTE FOR CHILD HEALTH) 19 March 1992 see the whole document ---	1-22
P,X	WO,A,94 24281 (IMMUNOLOGIC PHARMACEUTICAL CORPORATION) 27 October 1994 cited in the application see the whole document -----	1,4,7,19

INTERNATIONAL SEARCH REPORT

national application No.

PCT/US 95/04481

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 4-6, 18-19 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Intern al Application No
PCT/US 95/04481

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9308279	29-04-93	AU-A- 2794092	21-05-93
		AU-A- 2865492	21-05-93
		CA-A- 2121497	29-04-93
		CA-A- 2121498	29-04-93
		EP-A- 0623168	09-11-94
		EP-A- 0610335	17-08-94
		FI-A- 941757	16-06-94
		FI-A- 941758	16-06-94
		JP-T- 7502890	30-03-95
		JP-T- 7503362	13-04-95
		NO-A- 941370	08-06-94
		NO-A- 941371	15-06-94
		PT-A- 100978	31-01-94
		PT-A- 100979	31-01-94
		WO-A- 9308280	29-04-93
		ZA-A- 9208000	26-04-93
		ZA-A- 9208001	22-06-93
WO-A-9204445	19-03-92	AU-B- 655599	05-01-95
		AU-A- 8506291	30-03-92
		CA-A- 2091449	12-03-92
		EP-A- 0548200	30-06-93
		JP-T- 6500993	27-01-94
WO-A-9424281	27-10-94	AU-B- 4102693	08-11-94